Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity is supported by a clear improvement in Life Sciences, where 9% organic sales growth beat expectations and instrument demand improved as biopharma and academic markets recovered, while AI-related tailwinds helped drive stronger backlog trends. Diagnostics also strengthened, with pro forma gross margin reaching 62.4% and operating margin benefiting from a substantial Euroimmun right-sizing effort, including more than 500 positions reduced, which points to durable margin expansion as volume and mix improve. Its outlook is further reinforced by the sticky, high-margin Signals software franchise and the leadership position in newborn and autoimmune testing, where global scale, recurring demand, and expanding U.S. and ex-China growth opportunities support a constructive long-term fundamental thesis.

Revvity is viewed negatively because its largest growth drivers are not yet showing the acceleration embedded in the long-range plan, with Immunodiagnostics ex-China running at only +MSD/HSD% versus a 9–11% target and Life Sciences Solutions just returning to +LSD% after contracting in 2024 and 2025. Diagnostics also looks less durable than headline growth suggests, as 5% organic growth slightly missed the 5.5% forecast, newborn screening in China is weak, and reproductive health faces tougher comps from the annualization of the GEL contract alongside declining global birth rates. Competitive pressure is intensifying across reagents, immunodiagnostics, and scientific software, while the company’s downside scenarios imply meaningful valuation compression if the end-market recovery proves slower and longer-tailed than expected.